Fluconazole

證據等級: L5

預測適應症: 10 個

Fluconazole: From Fungal Infections to Pneumocystosis

One-Sentence Summary

Fluconazole is a triazole antifungal agent, established for treating systemic and mucosal fungal infections. The TxGNN model’s top-ranked prediction (punctate epithelial keratoconjunctivitis, 99.2%) has no supporting clinical trial or literature evidence and is explicitly flagged in the evidence pack as mechanistically implausible, so this report instead focuses on the only candidate with substantive evidence: Pneumocystosis (Pneumocystis jirovecii pneumonia), supported by 7 clinical trials and 20 publications, though the mechanistic rationale for efficacy remains contested.

Quick Overview

Item	Content
Original Indication	Systemic/mucosal fungal infections (antifungal, azole class) — Taiwan/SA-specific approved indication text not available (drug not registered locally)
Predicted New Indication	Pneumocystosis (Pneumocystis pneumonia)
TxGNN Prediction Score	97.82%
Evidence Level	L3
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this specific product is not available in the current dataset (data gap). Based on known pharmacology, fluconazole inhibits fungal 14α-demethylase (CYP51), blocking ergosterol synthesis in the fungal cell membrane — a mechanism effective against Candida and other classical yeasts.

Pneumocystis jirovecii, however, has an atypical cell membrane that largely lacks the conventional ergosterol pathway targeted by azoles, and it is intrinsically considered non-susceptible to fluconazole. Standard prophylaxis/treatment for pneumocystosis relies on trimethoprim-sulfamethoxazole, dapsone, atovaquone, or pentamidine — not azole antifungals.

The TxGNN high score most likely reflects a knowledge-graph clustering effect around “opportunistic/immunocompromised fungal infection” rather than a direct pharmacological rationale. The one directly relevant completed Phase 3 trial (NCT00000676) evaluated fluconazole for general fungal infection prophylaxis in AIDS patients — not specifically for Pneumocystis treatment or prevention — so the mechanistic case for this indication remains weak despite the volume of loosely related literature.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000676	Phase 3	Completed	500	Randomized comparison of fluconazole vs. clotrimazole troches for prevention of serious fungal infection in AIDS/ARC patients (nested in ACTG 081); the only trial directly involving fluconazole, but targets broad fungal prophylaxis, not Pneumocystis specifically (Relevance: A)
NCT00000991	Phase 3	Completed	600	Randomized trial of three anti-Pneumocystis regimens plus zidovudine for primary PCP prevention in advanced HIV; regimens traditionally exclude fluconazole (Relevance: B)
NCT04368559	Phase 3	Active, not recruiting	602	Rezafungin vs. standard antimicrobial regimen for invasive fungal disease prevention post-transplant; different drug/mechanism (echinocandin) (Relevance: C)
NCT00892359	Phase 2	Unknown	10	Pharmacokinetics of anidulafungin during CVVH; different drug, echinocandin class active against fluconazole-resistant strains (Relevance: C)
NCT02651038	Phase 4	Completed	10	Pharmacokinetics of micafungin during CVVHDF; different drug (Relevance: C)
NCT01042704	Phase 1	Completed	29	Bendamustine + lenalidomide + dexamethasone in relapsed multiple myeloma; unrelated to antifungal therapy, likely linked via opportunistic-infection risk in the study population (Relevance: C)
NCT06859424	Phase 2	Recruiting	358	GVHD prophylaxis platform trial post-transplant; not targeted at pneumocystosis (Relevance: C)

Note: Only NCT00000676 directly involves fluconazole, and it does not specifically test efficacy against Pneumocystis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26901377	2016	Review	Swiss Med Wkly	Overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia; notes fluconazole prophylaxis reduces invasive candidiasis in high-risk haemato-oncology patients (most directly relevant)
8818831	1996	Review	J Antimicrob Chemother	Treatment of fungal infections in AIDS, including fluconazole use for mucosal candidiasis
30508854	2018	Review	Dtsch Med Wochenschr	Update on opportunistic infection management; TMP-SMX remains standard for PCP prophylaxis/treatment
21418688	2010	Review	BMJ Clin Evid	Primary/secondary prophylaxis for HIV-related opportunistic infections
16288352	2005	Review	Klin Padiatr	Diagnosis/management of fungal infections and PCP in pediatric cancer patients
8016481	1993	Review	Semin Respir Infect	Infection after lung transplantation, including antifungal strategies
8397916	1993	Review	Curr Clin Top Infect Dis	Prophylaxis/treatment of infection in bone marrow transplant recipients
15826284	2005	Review	Mycoses	Invasive fungal infections after liver transplantation
11418871	2001	Review	Clin Infect Dis	CDC/IDSA/ASBMT guidelines summary for preventing opportunistic infections after HSCT
29514232	2018	Review	Clin Infect Dis	WHO guidelines for managing advanced HIV disease in a public health approach

None of the above are RCTs specifically testing fluconazole against pneumocystosis; all are reviews providing contextual/background support only.

South Africa Market Information

Fluconazole has 0 SAHPRA registrations in this dataset and is recorded as not marketed in South Africa. No product-level registration data is available for review.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: TFDA/local warning and contraindication data, and DDI data, are flagged as a blocking data gap in this evidence pack — see Conclusion below.)

Conclusion and Next Steps

Decision: Hold

Rationale:

Despite L3 evidence (7 trials, 20 publications), only one trial directly involves fluconazole, and it does not specifically address Pneumocystis efficacy; the mechanistic rationale is weak because P. jirovecii is intrinsically non-susceptible to azole antifungals, and the TxGNN score likely reflects an “opportunistic infection” knowledge-graph clustering artifact rather than true pharmacological plausibility.
The model’s top-ranked candidate (punctate epithelial keratoconjunctivitis) was excluded from this report due to zero supporting evidence and an explicit contraindicating rationale in the source data.

To proceed, the following is needed:

Resolution of the blocking data gap: TFDA/SAHPRA-equivalent PI warnings and contraindications (currently unavailable, prevents S1 safety assessment)
Confirmed mechanism-of-action data for fluconazole (currently a data gap)
A dedicated in vitro/preclinical study confirming (or refuting) fluconazole activity against Pneumocystis jirovecii, given standard-of-care already exists (TMP-SMX, dapsone, pentamidine, atovaquone)
Re-evaluation of lower-ranked candidates only if new trial or literature evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.